Australia's most trusted
source of pharma news
Thursday, 20 November 2025
Posted 20 November 2025 AM
The March PBAC Agenda dropped a week early with 32 companies chasing the first recommendations of 2026 for 21 new listings and 22 change to listings.
Novartis had the highest number of submissions at three - with nine other companies lining up two drugs for the PBACs consideration.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.